File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12072-021-10213-7
- Find via
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test
Title | Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test |
---|---|
Authors | |
Issue Date | 2021 |
Publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 |
Citation | The 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), Hybrid Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S53 How to Cite? |
Abstract | Background: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB).
Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender-matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥ 1 fibrosis stage, respectively.
Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range IQR 49.8–60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, p = 0.765) and at 3-years (5.9 vs. 5.5 kPa, p = 0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, p = 0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, p = 0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; p < 0.001), 3-year LS (6.4 vs 5.2 kPa; p < 0.001), and baseline ELF (8.8 vs. 8.3, p = 0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, p = 0.111) and regression (10.3% vs. 14.8%, p = 0.604) was similar in cases vs controls.
Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. |
Description | Poster presentation - Hepatitis B and Hepatitis D - no.H-79 |
Persistent Identifier | http://hdl.handle.net/10722/305537 |
ISSN | 2023 Impact Factor: 5.9 2023 SCImago Journal Rankings: 1.813 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Hui, WHR | - |
dc.contributor.author | Cheung, KSM | - |
dc.contributor.author | Liu, F | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2021-10-20T10:10:48Z | - |
dc.date.available | 2021-10-20T10:10:48Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | The 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), Hybrid Meeting, Bangkok, Thailand, 4-6 February 2021. In Hepatology International, 2021, v. 15 n. Suppl. 1, p. S53 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | http://hdl.handle.net/10722/305537 | - |
dc.description | Poster presentation - Hepatitis B and Hepatitis D - no.H-79 | - |
dc.description.abstract | Background: We assessed the effect of hepatitis B surface antigen (HBsAg) seroclearance on liver fibrosis regression in patients with chronic hepatitis B (CHB). Method: CHB patients with recent spontaneous HBsAg seroclearance (cases) were age- and gender-matched with treatment-naïve HBeAg-negative CHB infection (controls). Paired transient elastography (TE) and Enhanced Liver Fibrosis (ELF) measurements were performed at baseline and 3-year. Fibrosis progression and regression were defined as increase and decrease in ≥ 1 fibrosis stage, respectively. Results: In this interim analysis, 40 cases and 142 controls were recruited [median age 55.6 (interquartile range IQR 49.8–60.9), 53.8% male]. The median liver stiffness (LS) values were similar between the two groups at baseline (5.4 vs. 5.2 kPa, p = 0.765) and at 3-years (5.9 vs. 5.5 kPa, p = 0.455) respectively. The baseline controlled attenuation parameter values were significantly higher in cases vs controls (288 vs 251 dB/m, respectively, p = 0.001). The median ELF at 3-year was significantly higher than baseline in the controls (8.6 vs. 8.4, p = 0.033). All patients with severe steatosis had significantly higher baseline LS (5.9 vs. 4.8 kPa; p < 0.001), 3-year LS (6.4 vs 5.2 kPa; p < 0.001), and baseline ELF (8.8 vs. 8.3, p = 0.028). The proportion of patients with fibrosis progression (25.6% vs. 15.5%, respectively, p = 0.111) and regression (10.3% vs. 14.8%, p = 0.604) was similar in cases vs controls. Conclusion: Over a period of 3 years, fibrosis regression and progression were observed at a similar rate in patients with HBsAg seroclearance compared to patients with inactive CHB. Severe hepatic steatosis was associated with higher LS and ELF. | - |
dc.language | eng | - |
dc.publisher | Springer (India) Private Ltd. The Journal's web site is located at http://www.springer.com/medicine/internal/journal/12072 | - |
dc.relation.ispartof | Hepatology International | - |
dc.relation.ispartof | The 30th Annual Conference of the Asian Pacific for The Study of Liver (APASL), 2021 | - |
dc.title | Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum Enhanced Liver Fibrosis (ELF) test | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Mak, LY: lungyi@hku.hk | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Hui, WHR: huirex@connect.hku.hk | - |
dc.identifier.email | Cheung, KSM: cks634@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Mak, LY=rp02668 | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Cheung, KSM=rp02532 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.description.nature | abstract | - |
dc.identifier.hkuros | 327145 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | S53 | - |
dc.identifier.epage | S53 | - |
dc.publisher.place | India | - |
dc.identifier.partofdoi | 10.1007/s12072-021-10213-7 | - |